INDOCO REMEDIES is slightly downgraded to Slightly Positive due to an increasingly adverse environment
The independent financial analyst theScreener just slightly lowered the general evaluation of INDOCO REMEDIES (IN), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title confirms its rating of 3 out of 4 stars while its market behaviour remains unchanged and can be qualified as defensive. However, a marginally less favourable environment forces theScreener to downgrade slightly the title, which now shows an overall rating of Slightly Positive. As of the analysis date January 14, 2022, the closing price was INR 439.15 and its potential was estimated at INR 522.40.Indoco Remedies Ltd. Indoco Remedies Limited is an India-based company, which is engaged in the manufacture of pharmaceutical products. The Company primarily manufactures and markets Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The Company's geographical segments include India and Outside India. It offers products for various therapeutic categories, such as stomatologicals, respiratory, anti-infectives, gastrointestinal, pain/analgesics, gynecological, vitamins/minerals/nutrients, ophthal/otologicals and dermatology. Its domestic marketing divisions include INDOCO, SPADE, Warren NxGen, Warren Ace, Spera, Indoco Focus, Indoco CND, Warren Excel, Warren Vision, Eterna, Institution and Indoco IMPULSE. The Company's products include Sensodent-K, Homide, Carmicide, Renolen, Rexidin M, Febrex Plus, Zincoren, Otorex, Cloben G, Methycal, Tuspel, Scabex, Hemsyl, Karvol Plus, Durashape, Lignox, Sensoform Toothpaste, Kidodent Toothpaste, Rosuchek D, Otichek and Irimist.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.